Short answer
Theravance Biopharma, Inc. (TBPH) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $18M (up 15.0% year over year) with net income of −$5M.
Q1 2026 key financials · XBRL
- Revenue
- $18M
- +15.0% YoY
- Net income
- −$5M
- +63.7% YoY
- Operating margin
- -53.6%
- EPS (diluted)
- −$0.10
- +63.0% YoY
Source: XBRL data from the Theravance Biopharma, Inc. (TBPH) Q1 2026 10-Q on SEC EDGAR. USD.
Theravance Biopharma, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $17.7M, up 15% YoY from $15.4M under Viatris collaboration agreement
- YUPELRI sales $62.4M, up 7% YoY; implied Theravance share $21.9M
- R&D expense $5.8M, down 49% YoY from $11.5M amid restructuring and CYPRESS wind-down
- Restructuring targeting approximately 60% lower operating expenses, with approximately $70M annual savings beginning Q3 2026
- CYPRESS failed its primary endpoint; ampreloxetine program winding down and strategic alternatives review accelerating
Risk Factors
- Newly intensified strategic-review risk triggered by March 2026 CYPRESS failure and accelerated evaluation of alternatives, including a potential sale
- Most material commercial update: YUPELRI headwinds from evolved channel mix and lower realized net price
- Regulatory enforcement exposure: FDA actions including product seizure, injunctions, or civil monetary penalties for noncompliance
- Near-term competitive risk: Dupixent COPD approval adds a maintenance-treatment competitor to YUPELRI
- Financial risk: March 31, 2026 accumulated deficit of $864.6 million and quarterly net loss of $4.9 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Theravance Biopharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.